Scholarlink

Background <p>The rising use of antidepressants is critical for managing mental health disorders, but weight gain is a concerning side effect, particularly with certain classes like TCAs and SSRIs. This study aims to investigate weight changes in Omani patients prescribed paroxetine, fluoxetine, mirtazapine, or venlafaxine.</p> Method <p>A cross-sectional study conducted from January to June 2023 at Sultan Qaboos University Hospital recruited adults with mental disorders on these medications. Weight measurements were taken at baseline and follow-up, with clinically significant weight gain defined as a ≥ 7% increase.</p> Results <p>A total of 135 participants were analyzed, showing a mean weight gain of 5.54&#xa0;kg, with 60.7% experiencing significant weight gain. Mirtazapine and paroxetine exhibited the highest average weight increases (7.51&#xa0;kg and 8.05&#xa0;kg, respectively) compared to fluoxetine (0.69&#xa0;kg) and venlafaxine (4.32&#xa0;kg). No significant demographic factors influenced weight changes (<i>p</i> = 0.213).</p> Conclusion <p>The study highlights significant weight gain among Omani patients on antidepressants, particularly mirtazapine and paroxetine. This underscores the importance of monitoring weight in clinical practice and necessitates further investigations into individualized treatment strategies to manage both mental health and weight-related concerns.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of antidepressants on body weight in patients treated in a naturalistic setting in Oman

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月14日

查看全文
  • Latifa AL-Jahwari,
  • Mohammed Qutishat,
  • Mandhar Almaqbali,
  • Khalid Al Risi,
  • Mohammed AlBreiki,
  • Mohammed Albalushi,
  • Salim Al-Huseini

摘要

Background

The rising use of antidepressants is critical for managing mental health disorders, but weight gain is a concerning side effect, particularly with certain classes like TCAs and SSRIs. This study aims to investigate weight changes in Omani patients prescribed paroxetine, fluoxetine, mirtazapine, or venlafaxine.

Method

A cross-sectional study conducted from January to June 2023 at Sultan Qaboos University Hospital recruited adults with mental disorders on these medications. Weight measurements were taken at baseline and follow-up, with clinically significant weight gain defined as a ≥ 7% increase.

Results

A total of 135 participants were analyzed, showing a mean weight gain of 5.54 kg, with 60.7% experiencing significant weight gain. Mirtazapine and paroxetine exhibited the highest average weight increases (7.51 kg and 8.05 kg, respectively) compared to fluoxetine (0.69 kg) and venlafaxine (4.32 kg). No significant demographic factors influenced weight changes (p = 0.213).

Conclusion

The study highlights significant weight gain among Omani patients on antidepressants, particularly mirtazapine and paroxetine. This underscores the importance of monitoring weight in clinical practice and necessitates further investigations into individualized treatment strategies to manage both mental health and weight-related concerns.